» Articles » PMID: 27267795

Surrogate Markers of Long-term Outcome in Primary Total Hip Arthroplasty: A Systematic Review

Overview
Journal Bone Joint Res
Date 2016 Jun 9
PMID 27267795
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: High failure rates of metal-on-metal hip arthroplasty implants have highlighted the need for more careful introduction and monitoring of new implants and for the evaluation of the safety of medical devices. The National Joint Registry and other regulatory services are unable to detect failing implants at an early enough stage. We aimed to identify validated surrogate markers of long-term outcome in patients undergoing primary total hip arthroplasty (THA).

Methods: We conducted a systematic review of studies evaluating surrogate markers for predicting long-term outcome in primary THA. Long-term outcome was defined as revision rate of an implant at ten years according to National Institute of Health and Care Excellence guidelines. We conducted a search of Medline and Embase (OVID) databases. Separate search strategies were devised for the Cochrane database and Google Scholar. Each search was performed to include articles from the date of their inception to June 8, 2015.

Results: Our search strategy identified 1082 studies of which 115 studies were included for full article review. Following review, 17 articles were found that investigated surrogate markers of long-term outcome. These included one systematic review, one randomised control trial (RCT), one case control study and 13 case series. Validated surrogate markers included Radiostereometric Analysis (RSA) and Einzel-Bild-Röntgen-Analyse (EBRA), each measuring implant migration and wear. We identified five RSA studies (one systematic review and four case series) and four EBRA studies (one RCT and three case series). Patient Reported Outcome Measures (PROMs) at six months have been investigated but have not been validated against long-term outcomes.

Conclusions: This systematic review identified two validated surrogate markers of long-term primary THA outcome: RSA and EBRA, each measuring implant migration and wear. We recommend the consideration of RSA in the pre-market testing of new implants. EBRA can be used to investigate acetabular wear but not femoral migration. Further studies are needed to validate the use of PROMs for post-market surveillance.Cite this article: T. T. Malak, J. A. J. Broomfield, A. J. R. Palmer, S. Hopewell, A. Carr, C. Brown, D. Prieto-Alhambra, S. Glyn-Jones. Surrogate markers of long-term outcome in primary total hip arthroplasty: A systematic review. Bone Joint Res 2016;5:206-214. DOI: 10.1302/2046-3758.56.2000568.

Citing Articles

Evaluation and refinement of thresholds for early migration of total knee replacements as an estimator of late aseptic loosening: an updated systematic review of RSA and survival studies.

Puijk R, Singh J, Puijk R, Laende E, Plevier J, Nolte P Acta Orthop. 2025; 96():1-10.

PMID: 39776207 PMC: 11706017. DOI: 10.2340/17453674.2024.42574.


[Implant anchorage: In vivo and in vitro analyses : Clusters for implant anchorage and safety].

Kistler M, Schonhoff M, Reulbach M, Schleifenbaum S, Holscher-Doht S, Hurschler C Orthopadie (Heidelb). 2024; 53(7):519-526.

PMID: 38829401 DOI: 10.1007/s00132-024-04519-1.


Guideline for RSA and CT-RSA implant migration measurements: an update of standardizations and recommendations.

Kaptein B, Pijls B, Koster L, Karrholm J, Hull M, Niesen A Acta Orthop. 2024; 95:256-267.

PMID: 38819193 PMC: 11141406. DOI: 10.2340/17453674.2024.40709.


Trochleoplasty Provides Good Outcomes for Recurrent Patellofemoral Dislocations with No Clear Superiority across Different Techniques.

Tan S, Law G, Kim S, Sethi E, Lim A, Hui J J Clin Med. 2024; 13(10).

PMID: 38792556 PMC: 11122057. DOI: 10.3390/jcm13103009.


Radiographic signs and hip pain 5 years after THA with a cemented stem predict future revision for aseptic loosening: a prospective cohort study.

Lubbeke A, Barea C, Zingg M, Lauper N, Hannouche D, Garavaglia G Acta Orthop. 2024; 95:32-38.

PMID: 38284749 PMC: 10823869. DOI: 10.2340/17453674.2023.26190.


References
1.
McKee A, Farrell A, Pazdur R, Woodcock J . The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010; 15 Suppl 1:13-8. DOI: 10.1634/theoncologist.2010-S1-13. View

2.
Takenaga R, Callaghan J, Bedard N, Liu S, Gao Y . Which functional assessments predict long-term wear after total hip arthroplasty?. Clin Orthop Relat Res. 2013; 471(8):2586-94. PMC: 3705069. DOI: 10.1007/s11999-013-2968-9. View

3.
Furlan A, Pennick V, Bombardier C, van Tulder M . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34(18):1929-41. DOI: 10.1097/BRS.0b013e3181b1c99f. View

4.
Freeman M . Early migration and late aseptic failure of proximal femoral prostheses. J Bone Joint Surg Br. 1994; 76(3):432-8. View

5.
Thomas G, Simpson D, Mehmood S, Taylor A, McLardy-Smith P, Gill H . The seven-year wear of highly cross-linked polyethylene in total hip arthroplasty: a double-blind, randomized controlled trial using radiostereometric analysis. J Bone Joint Surg Am. 2011; 93(8):716-22. DOI: 10.2106/JBJS.J.00287. View